The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines

Now WHO experts annually formulates references on structure of both the 3rd, and 4 valent vaccines against influenza applied worldwide.

The purpose of work was the assessment of averted costs due to influenza vaccination with trivalent and quadrivalent vaccines in different age groups.

Material and methods. The analysis was carried out by a modeling from a societal perspective taking into account epidemiological data on the Russian Federation.

Results. According to data on structure of the allocated influenza viruses in the Russian Federation for 2006-2015, at vaccination coverage of 40% of the population, replacement of trivalent vaccines with quadrivalent vaccines could prevent in addition during the season on average 604 cases of influenza per 100 thousand children aged up to 3 years, 736 cases per 100 thousand children at the age of 3–6 years, 613 cases per 100 thousand children aged from 7 up to 14 years, 106 cases per 100 thousand citizens at the age of 15– 64 years, 19 cases per 100 thousand citizens at the age of 65 years and older. In the whole population replacement of trivalent vaccines with quadrivalent vaccines would allow to prevent during the season on average 181 cases of influenza per 100 thousand citizens in addition.

The averted cost is the greatest at vaccination of children of preschool and school age.

In general, the volume of the costs averted when replacing trivalent vaccines with quadrivalent vaccines against influenza could be increased for 2006–2015 on average by 15,0%, and during separate seasons this increasing could be more.

Replacement of a trivalent vaccines with quadrivalent vaccines could cause decrease in number of cases of influenza during the season by 265,8 thousand, and the costs averted could make 2,498 billion rubles.

Conclusions. Influenza vaccination with quadrivalent vaccines can increase clinical effectiveness and costs averted in comparison with trivalent vaccines. Replacement of trivalent vaccines with quadrivalent vaccines can be the most significant at vaccination of children of preschool and school age, and also in adults from risk groups and elderly people. Economic and clinical advantages of quadrivalent vaccines in comparison with the trivalent vaccines depend on a share in the general structure of a case rate of the strains of influenza B which aren’t relating to the line included in the trivalent vaccine.

1. Centers for Disease Control and Prevention: Quadrivalent Influenza Vaccine. [Text] (https://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm)

2. You, J.H. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. [Text] / J.H. You, W. Ming, P.K. Chan // BMC Infect Dis. – 2014. –14. – P. 618. doi:10.1186/s12879-014-0618-9.

3. Lobova T. G. Jevoljucionnaja izmenchivost’ virusov grippa B, cirkulirovavshih v Rossijskoj Federacii s 2005 po 2012 g. [Tekst] /T.G. Lobova [i dr.] // Voprosy vi-rusologii. – 2012. –№57 (6). – S. 22-26.

4. Centers for Disease Control and Prevention: Adjusted vaccine effectiveness estimates for influenza seasons from 2005-2016. [Text] Assessed on 12 August 2016 (https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm)

5. Simpson, C.R. Trivalent inactivated seasonal influenza vaccine effectiveness for the pre-vention of laboratory-confirmed influenza in a Scottish population 2000 to 2009 [Text] / C.R. Simpson [et al.] // Euro Surveill. – 2015. – 20 (8). – P. 21043.

6. Karpova L.S. Analiz jepidemii grippa A(H1N1)/Kalifornija/07/2009 v Rossii v sezon 2009 – 2010 godov [Tekst] / L.S. Karpova, I.G. Marinich, T.P. Stoljarova, N.M. Popovceva // Jepidemiologija i Vakcinoprofilaktika. – 2010. – № 3 (52). –C. 23-30.

7. Kinev M.Ju. Farmakojepidemiologicheskij analiz lechenija grippa i ego oslozh-nenij v uslovijah stacionara [Tekst] / M.Ju. Kinev, A.Ju. Petrov, O.A. Mel’nikova // Nauchnye vedomosti. Serija Medicina. Farmacija. – 2013. – № 18 (161). – Vypusk 23. – S. 169-175.

8. Otchet po ocenke jepidemiologicheskoj i jekonomicheskoj jeffektivnosti immuni-zacii vzroslogo rabotosposobnogo naselenija kommercheskoj grippoznoj vakcinoj «Grippol® pljus» proizvodstva OOO «NPO Petrovaks Farm» (v ramkah vypolnenija NIR po sovershenstvovaniju jepidemiologicheskogo nadzora pri primenenii medicin-skih immunobiologicheskih preparatov). [Tekst]. -2011. –23 s.

9. Centers for Disease Control and Prevention: Updated adjusted estimates of 2012–2013 seasonal influenza vaccine effectiveness in the United States. [Text]. Assessed on 30 April 2014. (http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf)

10. DiazGranados CA. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials [Text] / C.A. DiazGranados, M. Denis, S. Plotkin // Vaccine. – 2012. – 31. –P. 49–57.

11. Prilozhenija k General›nomu tarifnomu soglasheniju po tarifam na medicinskuju pomoshh› (medicin¬skie uslugi) i uslovijam oplaty medicinskoj pomoshhi, okazyvaemoj v ramkah dejstvujushhej Territori¬al›noj programmy objazatel›nogo medicinskogo strahovanija grazhdan Rossijskoj Federacii v Sankt-Peterburge na 2017 g. (www.spboms.ru)

12. Chuchalin A.G. Gripp u vzroslyh: metodicheskie rekomendacii po diagnostike, lecheniju, specificheskoj i nespecificheskoj profilaktike [Tekst] / A.G. Chuchalin, T.V. Sologub. – Sankt-Peterburg: NP-Print, 2014. – 192 s.

13. Ortqvist A. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area [Text] / A. Ortqvist, F. Granath, J. Askling, J. Hedlund // Eur Respir J. – 2007. – V.30. – P. 414–422.

14. Silujanova Je.V. Jevoljucionnaja izmenchivost› virusov grippa A(N3N2) i V v pe-riod 2003-2013 gg. v RF [Tekst]: avtoref. … k.m.n./ Je.V. Silujanova. –M.: NII viruso-logii im. D.I. Ivanovskogo. – M. 2014.

15. Ob itogah jepidsezona po grippu i ORVI 2013/2014. – Federal›naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka. [Tekst]. – Pis›mo ot 30 ijunja 2014 goda N 01/7281-14-32.

16. Ezhenedel›nyj jelektronnyj bjulleten› ECDC–ERB VOZ. Poslednie novosti o grippe v Evrope. Nedelja 20/2015 (11–17 maja 2015 g.) [Tekst] // (www.who.int)

17. Ob itogah jepidsezona po grippu i ORVI 2014/2015. – Federal›naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka po Vladimirskoj oblasti. [Tekst]. – Pis›mo ot 28.07.2015 № 1042.

18. Christopher S. Rationale for quadrivalent influenza vaccine [Text] /S. Christopher [et al.] // Human vaccines and immunotherapeutics. – 2012. –V.8. – №1. – P. 81–88.

19. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza [Text] / R.B. Belshe // Vaccine. – 2010. –№28S. – P. D45-D53.

20. Tjurina A.A. Farmakojekonomicheskoe obosnovanie jeffektivnosti primenenija vakciny Ul›triks dlja profilaktiki zabolevaemosti grippom i ostrymi respirator-nymi virusnymi infekcijami [Tekst] / A.A. Tjurina, V.B. Vasiljuk, K.A. Zaharov, T.V. Veselova, A.V. Zhukov // Zhurnal infektologii Prilozhenie. – 2015. –T. 7. – №4. – S. 37-42.

21. Rudakova A.V. Analiz jeffektivnosti zatrat na vakcinaciju ot grippa grazhdan trudosposobnogo vozrasta [Tekst] / A.V. Rudakova, S.M. Harit, A.N. Uskov, Ju.V. Lobzin // Medicina jekstremal›nyh situacij. – 2016. – №2 (56). – S. 25-29.